-
Sector Analysis
Venous Thromboembolism Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
According to GlobalData estimates, 2024 base year sales within the VTE market are approximately $3.93 billion across 7MM and will grow at a compound annual growth rate (CAGR) of 2.6% to reach $5.10 billion by the end of the forecast period. VTE is a disease that includes a myriad of life-threatening disorders ranging from PE to DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity
-
Sector Analysis
Venous Thromboembolism (VTE): Epidemiology Forecast to 2034
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially fatal condition which impedes blood flow by causing blood clots (thrombosis) (Wendelboe et al., 2021). In a VTE, a DVT is a clot that occurs only in the veins; DVT is commonly found in the legs and pelvis (proximally) but can also occur in the upper body (distally) (Henke et al., 2020). If the DVT travels from its original location through the circulatory system...
-
Product Insights
Hypertrophic Cardiomyopathy - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hypertrophic Cardiomyopathy - Global Clinical Trials Review, 2026" provides an overview of Hypertrophic Cardiomyopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Hypertrophic Cardiomyopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Neurogenic Orthostatic Hypotension (nOH): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Neurogenic Orthostatic Hypotension (nOH) - Global Clinical Trials Review, 2025" provides an overview of Neurogenic Orthostatic Hypotension (nOH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Neurogenic Orthostatic Hypotension (nOH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Thrombotic Microangiopathy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Thrombotic Microangiopathy - Global Clinical Trials Review, 2025" provides an overview of Thrombotic Microangiopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombotic Microangiopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Atrial Fibrillation Major Markets Drug Forecast and Market Analysis
The table below presents the key metrics for atrial fibrillation (AF) in the eight major pharmaceutical markets (8MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and Canada—during the forecast period from 2022–32. In 2022, GlobalData estimated that the global AF market reached $14.5 billion across the 8MM. The US makes up the majority of total global sales, contributing $10.7 billion (74%) due to the large prevalent AF population in the US, early adoption...
-
Product Insights
Acute Decompensated Heart Failure Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acute Decompensated Heart Failure - Global Clinical Trials Review, 2025" provides an overview of Acute Decompensated Heart Failure Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Decompensated Heart Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Dilated Cardiomyopathy (DCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Dilated Cardiomyopathy Therapeutics. - In 2024, more than three million diagnosed prevalent cases of DCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - The treatment of DCM is primarily focused on symptom management using beta-blockers, ACE inhibitors, ARBs, MRAs, and SGLT2 inhibitors. - Currently, 34 molecules are being developed for DCM across various stages of the pipeline. - Over the past 10...
-
Sector Analysis
Hypertrophic Cardiomyopathy (HCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypertrophic Cardiomyopathy Therapeutics. - In 2024, more than two million diagnosed prevalent cases of HCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - HCM management has traditionally relied on generic beta-blockers and calcium channel blockers to alleviate symptoms. - A total of 34 molecules are in development for HCM, including two drugs in the pre-registration stage, two drugs in Phase III, and...
-
Product Insights
Stroke Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Stroke - Global Clinical Trials Review, 2025" provides an overview of Stroke Clinical trials scenario. This report provides top line data relating to the clinical trials on Stroke. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.